Trials / Completed
CompletedNCT05056974
A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs
A Phase II Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs Among ART Stabilized HIV-1 Patients Who Undergo ART Interruption
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- United BioPharma · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase II proof-of-concept trial study to assess the safety and efficacy of UB-421 monotherapy plus chidamide in changing the latent HIV reservoir among ART-treated HIV-1 adults with stably viral suppression who undergo ART interruption.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UB-421 | 10 mg/kg, weekly UB-421 during the 8-week |
| DRUG | chidamide | 10 mg/dose, twice a week for 8 weeks |
Timeline
- Start date
- 2021-12-02
- Primary completion
- 2023-02-01
- Completion
- 2023-02-01
- First posted
- 2021-09-27
- Last updated
- 2023-02-15
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05056974. Inclusion in this directory is not an endorsement.